AstraZeneca USA.
Operational Technologies Corporation, 4100 NW Loop 410, Suite 100, San Antonio, Texas 78229, USA.
Theranostics. 2018 Jul 1;8(15):4016-4032. doi: 10.7150/thno.25958. eCollection 2018.
Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind to small molecular ligands or protein targets with high affinity and specificity, by acquiring unique three-dimensional structures. Aptamers have the advantage of being highly specific, relatively small in size, non-immunogenic and can be easily stabilized by chemical modifications, thus allowing expansion of their diagnostic and therapeutic potential. Since the invention of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like macular degeneration, cancer, thrombosis and inflammatory diseases. Furthermore, owing to the aforementioned advantages and unique adaptability of aptamers to point-of-care platforms, aptamer technology has created a stable niche in the field of diagnostics by enhancing the speed and accuracy of diagnoses. The aim of this review is to give an overview on aptamers, highlight the inherent therapeutic and diagnostic opportunities and challenges associated with them and present various aptamers that have reached therapeutic clinical trials, diagnostic markets or that have immediate translational potential for therapeutics and diagnostics applications.
适配体是短的单链 DNA 或 RNA 寡核苷酸,通过获得独特的三维结构,可以高亲和力和特异性地选择性结合小分子配体或蛋白质靶标。适配体具有高度特异性、相对较小的尺寸、非免疫原性和可通过化学修饰轻易稳定的优势,从而扩大了它们在诊断和治疗方面的潜力。自 20 世纪 90 年代初适配体发明以来,人们做出了巨大的努力,使它们在黄斑变性、癌症、血栓形成和炎症性疾病等疾病中具有临床相关性。此外,由于上述优势以及适配体对即时护理平台的独特适应性,适配体技术通过提高诊断的速度和准确性,在诊断领域中创造了一个稳定的利基市场。本文的目的是概述适配体,强调其固有的治疗和诊断机会以及相关挑战,并介绍已经进入治疗临床试验、诊断市场或具有即时转化为治疗和诊断应用潜力的各种适配体。